Su, Kevin Y. C.
Reynolds, John A. http://orcid.org/0000-0002-8962-4404
Reed, Rachel
Da Silva, Rachael
Kelsall, Janet
Baricevic-Jones, Ivona
Lee, David
Whetton, Anthony D.
Geifman, Nophar
McHugh, Neil
Bruce, Ian N.
,
Funding for this research was provided by:
Manchester Biomedical Research Centre
Article History
Received: 16 March 2023
Accepted: 17 July 2023
First Online: 29 July 2023
Declarations
:
: EthicalĀ approval was granted by the NRES Committee North West Greater Manchester West (REC: 09/H1014/64) and the local Research and Development departments at participant sites. All patients provided written informed consent at the time of study registration.
: Not applicable.
: Kevin Y C Su: Has received honoraria from Novartis pharmaceuticals for educational consulting. John A Reynolds: None to disclose. Rachel Reed: None to disclose. Rachael Da Silva: None to disclose. Janet Kelsall: None to disclose. Ivona Baricevic-Jones: None to disclose. David Lee: None to disclose. Anthony D Whetton: None to disclose. Nophar Geifman: None to disclose. Neil McHugh: None to disclose. Ian N Bruce has received grant/research support from GlaxoSmithKline; received consulting fees from GSK, UCB, Eli Lilly, BMS, Merck Serono, Aurinia and Astra Zeneca; and was a speaker for AstraZeneca, GlaxoSmithKline, and UCB.